BMYBRISTOL MYERS SQUIBB CO

• 2026-10-05 · Gallman Cari (EVP, General Counsel) · OTHER
• 2026-09-10 · Massacesi Cristian (EVP,Chief Med Offr,Head of Dev) · SELL
• 2026-09-03 · Short Bartie Wendy (EVP, Corporate Affairs) · OTHER

• 2026-05-07 · Mike Kelly · SELL · $15,001 - $50,000
• 2026-03-27 · Alan Armstrong · BUY · $1,001 - $15,000
• 2025-06-24 · Hon. Virginia Foxx · SELL · $1,001 - $15,000
• 2025-04-15 · Tommy Tuberville · SELL · $1,001 - $15,000
• 2025-01-15 · Hon. Julie Johnson · BUY · $1,001 - $15,000

• Bristol Myers jumps as two late-stage trials deliver positive results
• Why is Bristol-Myers Squibb stock surging today?
• Bristol Myers Squibb’s admilparant meets phase 3 IPF trial goal
• On the 12th Edition of Global Patient Week Bristol Myers Squibb and Saudi Schizophrenia Association 'Ehtiwaa' Collaborate to Support People Living with Schizophrenia Through the 'Small Wins' Initiative
• Bristol Myers posts late-stage trial win for multiple myeloma therapy Zenbexus